Escalating expenditures in stage ≥3 CKD and especially kidney failure made KRT the predominant cost driver, amplifying value from therapies that delay dialysis or transplantation. Finerenone was ...
SAN DIEGO — Dapagliflozin provides significant benefits in the treatment of chronic kidney disease (CKD) even when initiated in patients with the most severe stages of the disease who are typically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results